Bruker Corporation (NASDAQ:BRKR) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a note issued to investors on Thursday, July 6th. The brokerage currently has a $33.00 price objective on the medical research company’s stock. Zacks Investment Research‘s price target would suggest a potential upside of 15.91% from the stock’s previous close.

According to Zacks, “Bruker’s latest spree of product development is encouraging, the latest launch being the AVANCE NEO platform, a next-generation NMR console. The company’s strategic acquisition activity also encourages us. Also the cost-reduction action previously adopted by the company in its Nano-surfaces business played its role suitably. The company's solid cash balance on the back of improved free cash flow is indicative of strong fundamentals. Above all, the company’s raised revenue guidance also holds optimism indicating promising performance ahead. On the flip side, over the last one year, Bruker is trading below the Zacks categorized Instruments-Scientific industry. We are also discouraged with the company's year-over-year decline in organic revenues in the last reported first quarter. We are also concerned about currency fluctuations, competitive landscape and macroeconomic headwinds which are the major woes for Bruker.”

Other research analysts have also recently issued reports about the stock. Jefferies Group LLC reaffirmed a “buy” rating and set a $29.00 target price on shares of Bruker Corporation in a report on Friday, May 5th. Cleveland Research raised shares of Bruker Corporation from a “neutral” rating to a “buy” rating in a research note on Thursday, April 27th. Cowen and Company boosted their target price on shares of Bruker Corporation from $25.00 to $27.00 and gave the company a “market perform” rating in a report on Thursday, May 4th. Janney Montgomery Scott lowered shares of Bruker Corporation from a “buy” rating to a “neutral” rating in a report on Monday, March 27th. Finally, Deutsche Bank AG boosted their target price on shares of Bruker Corporation from $25.00 to $27.00 and gave the stock a “hold” rating in a research report on Monday, May 15th. One analyst has rated the stock with a sell rating, nine have given a hold rating and five have issued a buy rating to the company. Bruker Corporation currently has a consensus rating of “Hold” and a consensus target price of $27.00.

Bruker Corporation (NASDAQ:BRKR) traded down 2.28% during mid-day trading on Thursday, reaching $27.82. The company had a trading volume of 1,159,403 shares. The firm’s 50-day moving average price is $28.70 and its 200-day moving average price is $25.43. Bruker Corporation has a 12 month low of $19.58 and a 12 month high of $30.22. The stock has a market cap of $4.44 billion, a PE ratio of 29.53 and a beta of 1.10.

Bruker Corporation (NASDAQ:BRKR) last issued its earnings results on Thursday, August 3rd. The medical research company reported $0.23 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $0.20 by $0.03. The business had revenue of $414.90 million during the quarter, compared to the consensus estimate of $384.75 million. Bruker Corporation had a net margin of 9.35% and a return on equity of 26.88%. Bruker Corporation’s revenue was up 11.6% on a year-over-year basis. During the same period last year, the business posted $0.20 EPS. Equities research analysts forecast that Bruker Corporation will post $1.10 EPS for the current fiscal year.

Bruker Corporation declared that its Board of Directors has initiated a share repurchase plan on Friday, May 12th that allows the company to buyback $225.00 million in shares. This buyback authorization allows the medical research company to repurchase shares of its stock through open market purchases. Shares buyback plans are generally an indication that the company’s board of directors believes its stock is undervalued.

COPYRIGHT VIOLATION WARNING: This report was reported by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another website, it was illegally copied and reposted in violation of US & international trademark and copyright laws. The original version of this report can be accessed at https://www.thecerbatgem.com/2017/08/04/bruker-corporation-brkr-stock-rating-upgraded-by-zacks-investment-research-updated-updated-updated.html.

In related news, VP Mark Munch sold 73,724 shares of the business’s stock in a transaction that occurred on Thursday, June 8th. The shares were sold at an average price of $27.62, for a total transaction of $2,036,256.88. Following the completion of the sale, the vice president now directly owns 106,602 shares in the company, valued at $2,944,347.24. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, Director Richard Kniss sold 24,000 shares of Bruker Corporation stock in a transaction that occurred on Tuesday, June 13th. The shares were sold at an average price of $28.23, for a total transaction of $677,520.00. Following the transaction, the director now directly owns 46,753 shares in the company, valued at approximately $1,319,837.19. The disclosure for this sale can be found here. Over the last 90 days, insiders have acquired 78,120 shares of company stock valued at $2,047,366 and have sold 117,624 shares valued at $3,271,574. 35.20% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of the company. BlackRock Inc. boosted its position in shares of Bruker Corporation by 26,266.0% in the first quarter. BlackRock Inc. now owns 4,607,722 shares of the medical research company’s stock valued at $107,498,000 after buying an additional 4,590,246 shares during the last quarter. Norges Bank acquired a new position in shares of Bruker Corporation during the fourth quarter valued at about $45,298,000. FMR LLC boosted its position in shares of Bruker Corporation by 26.4% in the first quarter. FMR LLC now owns 7,146,000 shares of the medical research company’s stock valued at $166,716,000 after buying an additional 1,491,140 shares during the last quarter. MARSHALL WACE ASIA Ltd acquired a new position in shares of Bruker Corporation during the first quarter valued at about $28,963,000. Finally, Marshall Wace North America L.P. acquired a new position in shares of Bruker Corporation during the first quarter valued at about $28,963,000. Hedge funds and other institutional investors own 67.23% of the company’s stock.

About Bruker Corporation

Bruker Corporation designs and manufactures scientific instruments, and analytical and diagnostic solutions. Its segments include the Bruker BioSpin Group; the Bruker Chemicals, Applied Markets, Life Science, In-Vitro Diagnostics, Detection (CALID) Group; the Bruker Nano Group, and the Bruker Energy & Supercon Technologies (BEST) Segment.

Get a free copy of the Zacks research report on Bruker Corporation (BRKR)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Analyst Recommendations for Bruker Corporation (NASDAQ:BRKR)

Receive News & Stock Ratings for Bruker Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bruker Corporation and related stocks with our FREE daily email newsletter.